Silo Pharma, Inc. Annual Report: Key Investor Highlights & Risks

Overview

Silo Pharma, Inc. (NASDAQ: SILO) has published its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This comprehensive document provides critical insights into the company’s business, financial position, risk profile, and future prospects. Investors should pay close attention to the following key points, which may be sensitive to share price movements.

Key Financial and Corporate Information

• Common Stock Outstanding: As of March 27, 2026, Silo Pharma has 14,166,593 shares of common stock outstanding.
• Public Float: The aggregate market value held by non-affiliates as of June 30, 2025, was approximately \$5,325,513, based on a closing price of \$0.63 per share.
• Listing: The company’s common stock trades under the symbol SILO on the Nasdaq Stock Market LLC.
• SEC Compliance: Silo Pharma is a non-accelerated filer, a smaller reporting company, and not an emerging growth company. It has filed all required reports in the preceding 12 months.
• Dividend Policy: Silo Pharma has never paid cash dividends and has no plans to do so in the future, which may impact shareholder returns.

Principal Risk Factors and Potential Price Sensitivities

Financial Position & Capital Needs

• Limited Operating History: The company has only operated under its current business plan since September 2020 and has no history of profitable operations. It has not achieved positive cash flow during any fiscal year, including 2025. This raises concerns about ongoing viability and future profitability.
• Future Capital Requirements: Silo Pharma will require additional financing to fund its operations and execute its business plan. The company does not currently have arrangements to raise all the needed capital. If unable to raise funds, it may have to delay, scale back, or discontinue operations.
• Dilution Risk: Raising additional capital through equity or convertible securities may dilute existing shareholders’ ownership, and terms may include preferences adverse to current holders. Debt financing could impose restrictive covenants.

Therapeutics Business Risks

• Regulatory Compliance: Any significant breaches or changes in U.S. or foreign laws and regulations may disrupt development activities or business continuity.
• Clinical Trials & Expenses: Risks related to the timing and costs of clinical trials or other expenses could affect financial performance and share price.
• Intellectual Property: Risks related to IP protection, licensing, and potential disputes could impact the company’s competitive position and future prospects.
• Market Acceptance: There is uncertainty regarding the market acceptance of Silo Pharma’s products, which could impact revenues and profitability.
• Controlled Substances: Some product candidates may contain controlled substances, potentially generating public controversy and adverse publicity.

Digital Securities & Cryptocurrencies

• CBDC Impact: The launch of central bank digital currencies (CBDCs) could adversely impact Silo Pharma’s business model if it involves digital assets.
• Regulatory Uncertainty: Absence of federal regulations may result in digital assets being classified as securities, subjecting Silo Pharma to additional regulation and impacting operations.
• Liquidity Risks: Cryptocurrency assets are less liquid than cash and may not serve as reliable liquidity sources.
• Staking Risks: Staking digital assets may introduce risks of loss and liquidity constraints. The company has limited history in generating staking revenues, which may affect financial results.
• Competition: Silo Pharma faces competition from other companies staking and utilizing digital assets.

Risks Related to Securities & Market Conditions

• Reporting Compliance: Failure to remain current in reporting requirements could result in removal from NASDAQ, limiting liquidity and negatively impacting share price.
• Market Volatility: Silo Pharma’s common stock may be subject to extreme volatility. Adverse market and economic conditions could negatively affect business and share price.
• Dilution from Future Issuances: Future sales and issuances of securities could dilute ownership and cause share price declines.

COVID-19 Pandemic Impact

• Disruption & Uncertainty: The pandemic has caused significant disruption to financial markets, potentially impacting Silo Pharma’s ability to access capital. The ultimate impact remains uncertain and could materially affect operations and the value of common stock.
• Monitoring Required: Investors should monitor ongoing effects of COVID-19 and any other health epidemics on the company’s business, clinical trials, research programs, and overall economic environment.

Other Notable Points

• Change in Corporate Status: Silo Pharma was previously a business development company regulated under the Investment Company Act of 1940. In September 2018, it withdrew from this status and now operates as a commercial entity, which affects its accounting and reporting practices.
• Website Disclosure: The company’s website (www.silopharma.com) is not part of the Annual Report; all SEC filings are available via the SEC’s official site.

Forward-Looking Statements Disclaimer

This article contains forward-looking statements based on management’s current expectations. Actual results may differ materially due to risks and uncertainties discussed above and in the company’s Annual Report. Investors should not place undue reliance on these statements and are encouraged to read the full report for further details.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should perform their own due diligence and consult with a financial advisor before making any investment decisions.

View Silo Pharma, Inc. Historical chart here